The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.